12,037 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 12,037 shares of the company’s stock, valued at approximately $326,000.

Other institutional investors have also made changes to their positions in the company. CWM LLC lifted its holdings in shares of Guardant Health by 137.1% in the third quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after purchasing an additional 569 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Guardant Health in the third quarter valued at about $35,000. Nisa Investment Advisors LLC lifted its holdings in shares of Guardant Health by 26.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company’s stock valued at $102,000 after purchasing an additional 713 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Guardant Health in the third quarter valued at about $115,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Guardant Health by 50.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,421 shares of the company’s stock valued at $131,000 after purchasing an additional 1,491 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GH has been the topic of a number of research reports. Craig Hallum began coverage on Guardant Health in a report on Wednesday. They issued a “buy” rating and a $28.00 price target on the stock. Piper Sandler dropped their target price on Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. The Goldman Sachs Group dropped their target price on Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, April 15th. Guggenheim reiterated a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Finally, JPMorgan Chase & Co. dropped their target price on Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average target price of $39.27.

Insider Activity

In related news, insider Kumud Kalia purchased 2,187 shares of Guardant Health stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the transaction, the insider now directly owns 12,722 shares of the company’s stock, valued at approximately $226,706.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.20% of the stock is owned by company insiders.

Guardant Health Price Performance

Guardant Health stock opened at $17.35 on Friday. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $41.06. The stock’s 50 day moving average is $18.84 and its 200-day moving average is $22.96. The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -4.05 and a beta of 0.87.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The firm had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Equities research analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.